Companies are paying more for late-stage products because drugs are worth more. Data from IMS Health shows that there were nearly twice as many $500 million drugs in 1997 as there were in 1993.
You may also be interested in...
Acutus Medical Inks Marketing Deal With Biotronik; Mapping Its Way To Electrophysiologists Outside US
Biotronik will help Acutus to bring its cardiac mapping software and guidance system to electrophysiologists worldwide.
Manufacturers Should Map Processes, Bolster Quality Culture To Tackle Data Integrity Problems in The Microbiology Lab
To reduce the opportunity for data integrity failures in the microbiology lab, manufacturers should map out the workflow so that activities and expectations for employees are clearly spelled out. Having formalized processes will ensure that employees don’t cut corners.
Companies can have their EU centralized marketing authorization application and submission for an Article 58 opinion (on medicines for use in non-EU countries) reviewed in parallel by the European Medicines Agency. The simultaneous assessment can be helpful when drugs and vaccines are needed for both EU and non-EU populations.